Last reviewed · How we verify
Study of Policosanol to Improve High on Clopidogrel Platelet Reactivity After Percutaneous Coronary Stent Implantation(Spirit) (spirit)
Thrombotic event is one of the most serious complications of coronary artery disease, which often result in myocardial infarction and even death. Even according to the standard guidelines for antiplatelet therapy, there are still 6% to 15% of patients occur thrombotic events, in high-risk patients, the proportion is higher, this phenomenon is called anti-platelet drug resistance in clinical practice The aim of this multicenter prospective, randomized, controlled study is to observed policosanol on aspirin or clopidogrel resistance in patients with platelet aggregation after Percutaneous Coronary Stent Implantation (PCI) and occurrence of platelet aggregation and short-term prognosis to find new ways to the prevention of platelet aggregation .
Details
| Lead sponsor | Shenyang Northern Hospital |
|---|---|
| Phase | Phase 4 |
| Status | COMPLETED |
| Enrolment | 350 |
| Start date | 2011-03 |
| Completion | 2013-09 |
Conditions
- Coronary Artery Disease
Interventions
- high maintenance clopidogrel
- routine dual antiplatelet
- policosanol plus dual antiplatelet
Primary outcomes
- reversion rate of HPR — 30 days
reversion was defined as platelet aggregation \<65%
Countries
China